...antigens in preclinical through Phase I testing for the disease. At least one other company, Virobay Inc....
...not specific for any one HLA allele, the strategy could lead to overly broad immunosuppression. Virobay...
...Mentioned ImmunoMolecular Therapeutics LLC, Broomfield, Colo. JDRF, New York, N.Y. Tolerion Inc., Portola Valley, Calif. Virobay Inc....

...with vehicle. Next steps could include identifying and testing CTSS inhibitors in models of lupus. Virobay Inc....
...in Phase I testing to treat pain and in discovery research to treat Alzheimer's disease. Virobay...

...Palo Alto, Calif.) named James Welch CFO and James Shaffer CBO. Welch was CFO at Virobay Inc....

...Date announced: 2014-10-31 Type: IPO Underwriters: Piper Jaffray; JMP Securities; Cantor Fitzgerald; Summer Street Note: ViroBay...

...IPO on NASDAQ and now plans to sell 3.8 million shares at $12-$14. In September, Virobay...

...proposed IPOs on NASDAQ Virobay plans to sell 3.8 million shares at $12-$14. At $13, Virobay...
...$169 million. Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners are underwriters. Virobay...

...9/15/14 Up to $65M Ph II Kolltan Pharmaceuticals Inc. 9/12/14 Up to $86.3M Ph I Virobay Inc....

...on NASDAQ underwritten by Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners. Virobay...